虎踞乙肝胶囊联合阿德福韦酯抗慢性乙肝肝纤维化的临床研究

发布时间：2018-04-11 15:54

本文选题：虎踞乙肝胶囊 + 阿德福韦酯　；参考：《辽宁中医杂志》2015年05期

【摘要】：目的:观察虎踞乙肝胶囊联合阿德福韦酯(ADV)治疗慢性乙肝肝纤维化的疗效。方法:采用随机对照方法,将59例慢性乙肝患者随机分为治疗组和对照组,对照组35例单独应用口服阿德福韦酯治疗,治疗组24例则在对照组治疗基础上加用口服虎踞乙肝胶囊。治疗6个月,治疗前后检测ALT、HBV-DNA、e抗原以及Piii P、HA、TGF-β1并进行统计学分析。结果:治疗组ALT复常率、HBV-DNA以及e抗原转阴率均优于对照组,但无统计学性差异(P0.05);两组肝纤维化指标Piii P、HA及肝纤维化刺激因子TGF-β1均显著降低,且治疗组降低程度明显优于对照组,有统计学差异(P0.05)。结论:虎驹乙肝胶囊联合ADV治疗慢性乙型肝炎在降低肝纤维化指标、抑制HSC刺激因子TGF-β1方面较单用ADV具有更好的疗效,值得进一步临床推广。
[Abstract]:Objective: to observe the curative effect of Huzhugan capsule combined with adefovir dipivoxil (ADV) on chronic hepatitis B liver fibrosis.Methods: 59 patients with chronic hepatitis B were randomly divided into treatment group and control group. 35 patients in control group were treated with adefovir alone.In the treatment group, 24 cases were treated with Huzhu Hepatitis B capsule on the basis of control group.After 6 months of treatment, alt HBV-DNA antigen and Piii PHAA TGF- 尾 1 were detected before and after treatment.Results: the rate of ALT normalization and the conversion rate of HBV-DNA and e antigen in the treatment group were higher than those in the control group, but there was no statistical difference between the two groups (P 0.05), the liver fibrosis index Piii Phiha and the hepatic fibrosis stimulating factor TGF- 尾 1 in the treatment group were significantly lower than those in the control group, and the degree of the decrease in the treatment group was significantly higher than that in the control group.There was statistical difference (P 0.05).Conclusion: Huju Hepatitis B capsule combined with ADV in the treatment of chronic hepatitis B has better curative effect in reducing liver fibrosis index and inhibiting HSC stimulating factor TGF- 尾 1 than ADV alone, which is worthy of further clinical promotion.
【作者单位】：南京市第二医院;
【基金】：国家自然科学基金资助项目(81000997)
【分类号】：R512.62;R575.2

【参考文献】